Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:39:56 Source:opinionsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:I'm a cruise ship worker...these are the FIVE things smart passengers always do onboard
Next:Candice Swanepoel wows in a shimmering black flared jumpsuit as she joins ab
You may also like
- Sweden beats France, Britain relegated after losing to Norway at hockey worlds
- Wyatt Johnston scores in OT, Stars beat Golden Knights 3
- Kawhi Leonard ruled out with knee issue as Clippers face Mavs in Game 4
- Lyon to face Barcelona in the Women's Champions League final after ousting PSG
- These hilarious notices will make you do a double take
- Salma Hayek dresses up as Frida Kahlo to join Madonna on stage at her Mexico concert
- Marlins place struggling outfielder Avísail García on injured list
- Kyle Tucker homers as the Astros beat the Rockies 8
- Sienna Miller's lookalike daughter Marlowe, 11, makes her first ever red carpet appearance